Edenbridge Pharmaceuticals, LLC announced that DARTISLA ODT (glycopyrrolate) is now available by prescription in the United States through Phil, Inc. (Phil), the commercialization partner and eHub for DARTISLA ODT, as well as in retail pharmacies throughout the country.
The FDA approved Dartisla ODT for adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer on December 16, 2021. DARTISLA ODT is manufactured by Catalent using their proprietary Zydis®* orally disintegrating tablet delivery technology to create a freeze-dried tablet that disperses almost instantly in the mouth without water.
To ensure access to patients in need, Edenbridge is sponsoring the DARTISLA ODT Copay Program, which allows eligible patients to obtain the product for as little as $0 when filled through Phil or $20 when filled at other pharmacies.
Phil previously announced a partnership with Impel NeuroPharma, Inc. in support of Trudhesa™ (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) to provide technology-powered patient support and distribution services through Phil’s proprietary workflow to enhance the patient’s access to therapy. Trudhesa is indicated for the acute treatment of migraine with or without aura in adults.
Phil was founded to offer pharmaceutical manufacturers an innovative approach to patient access services. Phil’s Patient Access Platform leverages tech in a meaningful way to expedite speed-to-therapy while offering an enhanced experience for providers and patients.
Phil is a software therapy deployment platform, offering pharmaceutical manufacturers a modern alternative to traditional access, affordability and distribution options.
Through its digital stakeholder experiences, patient access services, market access solutions and distribution models, pharma manufacturers are able to deliver affordable and timely therapy access to patients.
Takeaway: Phil, Inc. continues to disrupt the traditional hub services provider market by simplifying the patient onboarding process